---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-011459"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:07:46.578387+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Passage Bio reports Q2 net loss $16M; advances upliFT-D trial, out-licenses programs to GEMMABio

## Summary
- Enrolled first FTD-GRN patient in Cohort 2 of upliFT-D trial; FDA agreed to expand trial to FTD-C9orf72 patients.
- Out-licensed pediatric LSD programs to GEMMA Biotherapeutics; initial payments $10M, potential milestones up to $114M plus royalties.
- Cash $91.8M as of June 30, 2024; cash runway extended to end of Q2 2026.
- Net loss $16.0M ($0.26/share) vs $23.9M ($0.44/share) in Q2 2023; R&D and G&A expenses decreased.
- Plan to present updated safety and biomarker data from Cohort 1 at ISFTD2024 in September.

## SEC filing metadata
- accession: 0001558370-24-011459
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000155837024011459/0001558370-24-011459-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000155837024011459/pasg-20240808x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-011459
- JSON: https://secwatch.observer/filing/0001558370-24-011459.json
- Plain text: https://secwatch.observer/filing/0001558370-24-011459.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.